Get the Stockscreener App
9.01
0.55%
-0.05
Indivior Plc stock is traded at $9.01, with a volume of 1.48M.
It is down -0.55% in the last 24 hours and down -9.81% over the past month.
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.
See More
Previous Close:
$9.06
Open:
$9.05
24h Volume:
1.48M
Relative Volume:
1.44
Market Cap:
$1.18B
Revenue:
$1.12B
Net Income/Loss:
$5.00M
P/E Ratio:
901.00
EPS:
0.01
Net Cash Flow:
$-383.00M
1W Performance:
+0.78%
1M Performance:
-9.81%
6M Performance:
+4.89%
1Y Performance:
-53.22%
1-Day Range:
$9.00
$9.25
1-Week Range:
$8.91
$9.535
52-Week Range:
$7.33
$19.13
Indivior Plc Stock (INDV) Company Profile
Compare INDV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDV
Indivior Plc
|
9.01 | 1.18B | 1.12B | 5.00M | -383.00M | 0.01 |
|
ZTS
Zoetis Inc
|
148.67 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.22 | 45.62B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.71 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.65 | 15.60B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
284.73 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Indivior Plc Stock (INDV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-23-24 | Initiated | Piper Sandler | Overweight |
| Apr-03-24 | Initiated | Craig Hallum | Buy |
| Jul-13-23 | Initiated | Northland Capital | Outperform |
Indivior Plc Stock (INDV) Latest News
Press Release Distribution & PR Platform - ACCESS Newswire
Where are the Opportunities in (INDV) - news.stocktradersdaily.com
Substance Abuse Treatment Market Projected To Witness - openPR.com
Indivior PLC (INDV): Is This Deeply Undervalued Stock a Hidden Gem? - The Acquirer's Multiple
Indivior schedules Q1 2025 results release and webcast By Investing.com - Investing.com South Africa
INDV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Indivior PLC Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Indivior schedules Q1 2025 results release and webcast - Investing.com
Investors who lost money on Indivior PLC(INDV) should contact Levi & Korsinsky about pending Class ActionINDV - ACCESS Newswire
Indivior to Release Q1 2025 Financial Results and Host Webcast - TipRanks
Indivior PLC Announces Board Appointments - MarketScreener
Opioid Use Disorder Market Generated Opportunities, Future - openPR.com
Indivior PLC Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationINDV - ACCESS Newswire
Opioid Withdrawal Treatment Market Emerging Trends and Growth - openPR.com
Indivior PLC Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More InformationINDV - ACCESS Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Indivior PLC(INDV) Shareholders - ACCESS Newswire
Indivior PLC Sees Change in Major Holdings by Rubric Capital - TipRanks
Naloxone Market Is Booming Worldwide | EMERGENT, Indivior PLC, Akorn, Inc, Hikma Pharmaceuticals PLC - openPR.com
Indivior: A Complicated Story Of Both Declining Revenue And Strong Financials - Seeking Alpha
Indivior PLC Updates Share Capital and Voting Rights - TipRanks
(INDV) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Is Indivior PLC (INDV) the Best Stock to Buy According to Howard Marks’ Oaktree Capital Management? - Insider Monkey
Levi & Korsinsky Notifies Shareholders of Indivior PLC(INDV) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Indivior PLC Announces Change in Major Holdings - TipRanks
Indivior PLC announces AGM details, addresses remuneration policy By Investing.com - Investing.com Canada
Indivior schedules 2025 AGM for May 8 By Investing.com - Investing.com South Africa
Indivior PLC announces AGM details, addresses remuneration policy - Investing.com
Indivior schedules 2025 AGM for May 8 - Investing.com
Indivior PLC Publishes 2025 AGM Notice and Governance Updates - TipRanks
Substance Abuse Treatment Market Set to Witness Significant - openPR
Naloxone Market 2025 Growth, Business Opportunities, - openPR
Madison Avenue Partners, LP Increases Stake in Indivior PLC - GuruFocus
Indivior PLC Sees Change in Major Holdings - TipRanks
Indivior said FDA has delayed approval of SUBLOCADE label changes - MSN
Indivior Insiders Placed Bullish Bets Worth US$1.42m - Yahoo
Expert: FDA Approves Buprenorphine Injections Label Change, Accelerating Access to Opioid Use Disorder Treatment - Pharmacy Times
Indivior releases 2024 annual financial report By Investing.com - Investing.com South Africa
Indivior Announces Executive Share Vesting Under Deferred Bonus Plan - TipRanks
Indivior PLC Publishes 2024 Annual Report - TipRanks
Indivior releases 2024 annual financial report - Investing.com
Indivior CEO Receives Conditional Share Award Under Deferred Bonus Plan - TipRanks
Madison Avenue Partners Increases Stake in Indivior PLC - TipRanks
Global Naloxone Market to Witness Remarkable Growth with Indivior PLC, Akorn, Inc., Hikma Pharmaceuticals PLC, - EIN News
Indivior Announces Joseph Ciaffoni Appointed Chief Executive Off - GuruFocus.com
Indivior CEO’s Share Interests Updated Following LTIP Award Release - TipRanks
Indivior Director Increases Shareholding, Signaling Confidence - TipRanks
Indivior Plc Stock (INDV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):